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Purpose/Objective: To evaluate the impact of adjuvant 
taxane-platinum-based chemoradiation with preventive para-
aortic zone irradiation to outcome improvement in 
endometrial cancer II-III FIGO patients.  
Materials and Methods: From January 2008 to April 2014 
database of 250 EC patients’ medical histories and outpatient 
cards was analyzed retrospectively; all cases were re-staged 
according to 2009 FIGO classification  
115 patients with endometrial cancer II-III stage were 
considered eligible and were included in the study in two 
arms. 49(43%) pts. were enrolled in research group A. All of 
them undergone total hysterectomy , with pelvic 
lymphadenectomy in 18(36,7%), pelvic-paraaortic 
lymphadenectomy - in 8(16%) of them, followed by adjuvant 
chemoradiation. Image-guided external beam radiotherapy 
combined with brachy had been performed in 100% , 33(61%) 
patients were supplemented with para-aortic lymph node 
irradiation to the level of Th12-L2. All patients then received 
2-6 courses of taxane-platinum adjuvant chemotherapy. Total 
mean dose to pelvic (obturator, internal/ external/ common 
iliac) and para-aortic lymphnodes TD44Gy (30-50Gy) was 
achieved, with increase to 60Gy (36-74) in the vaginal vault 
because of Ir-192 HDR brachytherapy. 
66 (57%) patients were enrolled in control arm B; all of them 
undergone total hysterectomy, with pelvic lymphadenectomy 
in 14 (21%) and pelvic-paraaortic lymphadenectomy in 7 (10, 
6%) of them, followed by conventional external beam 
radiotherapy on the pelvic region TD 40-44Gy, added by Co-
60 HDR brachytherapy to vaginal cuff.  
Results: The median follow-up was 12 months (range, 1-79 
months). We registered the significant improvement in 
overall and disease-free survival in arm A, with 11% decrease 
of loco-regional relapse rate (from 20% to 9% in stage II pts., 
from 36% to 21% in stage III pts.) and 11% decrease (from 22% 
to 11%) of distant metastasis rate in stage III pts. Treatment 
was tolerable: no significant difference in adverse effect 
rates and grade was registered in arm A inspite of irradiation 
field extention, mainly because of specific therapeutic 
prevention.  
Conclusions: Adjuvant taxane-platinum-based 
chemoradiation with preventive para-aortic zone irradiation 
improves one year overall survival, disease-free and cancer-
specific survival for patients with II-III FIGO with acceptable 
side effects rate. 
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Purpose/Objective: This is a retrospective study, to evaluate 
the effect of treatment breaks due to anemia and blood 
transfusions on treatment response in cervical cancer 
patients who completed the standard treatment.  
Materials and Methods: Medical records of 151 patients, 
from Nov. 1st 2012 to Oct.31st 2013, were reviewed for 
demographic variables, stage of the disease, total dose 
delivered, degree of anemia, episodes of blood transfusions, 
treatment breaks and treatment duration. RECIST criteria for 
treatment response, FIGO for cervical cancer staging and 
RTOG for degree of anemia were used. The standard cervical 
cancer treatment used was concurrent chemo- radiotherapy 
followed by LDR intracavitary brachy therapy. The CHI square 
testing and 95 % significance level was applied. 
Results: A total of 151 cervical cancer patients were booked 
over the study period, Of which:- Stage IA & IB2 10%, IIA-IIB 
29%, IIIA- IIIB 48.4%, and IV 16.6%. Of the total, 41 patients 
did not start treatment in spite of booking. The rest 110 
(72.6%) started treatment with curative and palliative intent, 
Out of which,64 patients completed curative treatment 
course, of which 90.4% had good response and 9.6% didn't 
respond and/or disease progressed on treatment. There were 
40 episodes of blood transfusions, the 42.5% given before 
commencement of treatment and 57.5% during the course. 
Most of the treatment breaks were due to consequences of 
anemia and mainly for blood transfusions. The mean 
treatment break was 2.93 days. Those who presented with < 
10 HB, needed more transfusions during the course (p< 0.01). 
Response rate of those with HB >_ 10 gm at presentation was 
not significantly better than those with HB < 10 gm and 
needed transfusions in the course and short treatment breaks 
( p > 0.05).  
Conclusions: Cervical cancer patients who presented low HB 
at presentation, in spite of HB buildup transfusions at the 
beginning of the treatment are likely to need more 
transfusions during the course and their treatment response 
is not significantly different from those who started 
treatment with normal HB. High number of advanced cases 
and drop outs calls for an extensive study of KAP toward 
cancer and its treatment in the study society. 
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Purpose/Objective: Rectal dose defined as a point dose in 
ICRU 38 is not a good surrogate for actual dose delivered. 
Image based brachytherapy using CT or MRI allows for 
volumetric assessment of radiation dose. The possibility of 
developing rectal complications is best quantified from 
measuring dose to 2cc (D2cc) of rectum. In this study we 
investigated the effect of rectal distension on rectal dose 
parameters in patients of locally advanced cervical cancers 
undergoing CT based high dose rate brachytherapy and 
generated a model to predict the increase in D2cc with 
increasing rectal distension. 
Materials and Methods: Between January and October 2013, 
'planning CT scans' of 30 locally advanced cervical cancer 
patients undergoing three dimensional brachytherapy were 
reviewed retrospectively. Rectum was contoured from 
rectosigmoid junction superiorly until the ischial tuberosity 
inferiorly. The maximum rectal distension (MRD) was 
measured as the largest anterior-posterior diameter of the 
rectum opposite to the line joining the central tandem tip 
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and the cervical collar. A dose volume histogram was 
generated and a dosimetric correlation of MRD with dose to 
2cc (D2cc), dose to 1cc (D1cc), maximum and mean rectal 
dose was calculated using spss software version 19. 
Results: The mean MRD was 3.11cm (range 2.32-3.77cm). 
D1cc, D2cc, mean rectal dose and maximum rectal doses 
were 3.51 Gy, 3.04 Gy, 1.63 Gy and 4.95 Gy per treatment, 
respectively. Statistical analysis revealed an increase in D2cc 
(p=0.02) and D1cc (p=0.05) with increasing rectal distension. 
Further it is possible to predict the increase in D2cc with 
increasing rectal distension using the linear regression model: 
'Increase in D2cc in cGy = 17.74 + 92.22 x Increase in rectal 
distension in cm'. 
 
Conclusions: D2cc increases significantly with increasing 
rectal distension in HDR brachytherapy for cervical cancer 
patients. Minimizing rectal distension by simple measures like 
overnight fasting, mild laxatives and enema are likely to 
minimize potential rectal toxicity. Hence efforts to decrease 
rectal distention during brachytherapy should be considered.  
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Purpose/Objective: Endometrial cancer is the commonest 
gynaecological malignancy with an increasing incidence. It is 
unclear whether patients with early stage endometrial cancer 
treated with surgery and no adjuvant therapy require regular 
gynaecological follow-up. 
Materials and Methods: Retrospective analysis of all cases of 
early stage endometrial cancer treated with surgery and no 
adjuvant therapy presenting with recurrence over a thirteen 
year time period in a single centre. Case notes and electronic 
records were reviewed to determine whether the recurrence 
presented symptomatically or was detected clinically on 
follow-up. The intent of treatment at recurrence was 
analysed to determine the 2-year survival for this patient 
group. 
Results: 35 patients were included, who presented with 
recurrence between 2000 and 2013. 10 patients (29%) were 
detected clinically on routine follow-up with 25 patients 
(71%) presenting symptomatically. 20 patients (57%) were 
treated with palliative intent (7 chemotherapy, 8 External 
Beam Radiotherapy (EBRT), 4 hormone treatments and 1 best 
supportive care) and 15 patients (43%) were treated with 
radical intent (9 EBRT followed by brachytherapy, 4 
brachytherapy alone and 2 receiving EBRT alone). Median 
follow-up was 22 months. Median survival overall was 23 
months, with palliative treatment was 10 months and with 
radical treatment was 53 months. 2-year survival following 
recurrence overall was 51.6%, following radical treatment 
was 78.5%, and following palliative treatment was 29.4%.  
Conclusions: With 71% of patients presenting with recurrence 
having symptoms, it would appear on the surface to be 
reasonable to alter the model of follow-up to be more 
patient-centred, with symptoms triggering referral rather 
than routine review. However, in view of 80% of patients 
whose recurrence is detected at Routine Follow-Up, going on 
to have radical treatment, it may be more appropriate to 
offer patients the choice of Routine Follow-Up or a telephone 
review/self-referral service. In times of pressure on NHS 
resources this may be a suitable way of managing this cohort 
of patients. 
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Purpose/Objective: The position of the vagina could be 
highly variable due to differences of bladder and rectal 
filling. In order to ensure adequate target coverage, RTOG 
first introduced ITV accounting for individualized organ 
motion affected by bladder filling. We investigate the 
magnitude of vaginal displacement along the treatment in 
patients treated with post-operative IMRT for gynaecological 
cancer. We evaluate the subsequent dosimetric coverage loss 
and look for any correlation with bladder and rectal filling. 
Materials and Methods: We retrospectively analyzed 27 
consecutive patients treated in our institution between July 
2012 and July 2014 with IMRT for post-operative treatment of 
gynaecological cancer.  
All patients underwent empty and full bladder CT simulation 
(CT planning). This procedure was repeated as a control 3 
weeks after (CT-control). Both sets of CTs were registered. 
The delineation of the volumes and the definition of ITV were 
performed following the RTOG guidelines in both CTs. 
ITV displacement was measured as the coordinates difference 
(in three axes) between the center-of-mass of both ITV, 
expressed in absolute value. With these values we calculated 
the 3D vector. 
The PTV was created by adding 0.7cm (margin) to ITV and 
CTV-node. Treatment planning was done on full bladder CT-
planning with IMRT. Plans were optimized and normalized to 
deliver 100% prescribed dose to 97% of PTV. 
These plans were recalculated (but not optimized) on the full 
bladder CT-control. 
